Fractyl Health nominates RJVA-002 GIP/GLP-1 gene therapy; positive 13-week preclinical data on RJVA-001

FRACTYL HEALTH, INC.

Nominated RJVA-002 as first GIP/GLP-1 pancreatic gene therapy lead candidate for obesity.
RJVA-001 shows sustained weight and blood sugar control at 13 weeks in DIO mice on high-fat diet.
Over 10% of islet cells expressed GLP-1 after single dose; no safety signals.
Data independently validated by Dr. Randy Seeley at University of Michigan.
Fractyl plans to use durable efficacy results for RJVA-001 FIH data package.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.